Cargando…

SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. METHODS: A retrospective, observation...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamez-Perez, Héctor Eloy, Delgadillo-Esteban, Enrique, Soni-Duque, David, Hernández-Coria, Mayra Ivonne, Tamez-Peña, Alejandra Lorena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493113/
https://www.ncbi.nlm.nih.gov/pubmed/28680862
http://dx.doi.org/10.1186/s40200-017-0308-4
_version_ 1783247447579951104
author Tamez-Perez, Héctor Eloy
Delgadillo-Esteban, Enrique
Soni-Duque, David
Hernández-Coria, Mayra Ivonne
Tamez-Peña, Alejandra Lorena
author_facet Tamez-Perez, Héctor Eloy
Delgadillo-Esteban, Enrique
Soni-Duque, David
Hernández-Coria, Mayra Ivonne
Tamez-Peña, Alejandra Lorena
author_sort Tamez-Perez, Héctor Eloy
collection PubMed
description BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. METHODS: A retrospective, observational study. Inclusion criteria for patients were a previous diagnosis of type 2 diabetes mellitus, age > 18 years, patients receiving either dapagliflozin 10 mg and/or canagliflozin 300 mg. We excluded pregnant patients, patients with type 1 diabetes mellitus and acute metabolic complications of diabetes. Patients included in the analysis were enrolled in a health plan at least 6 months prior to the index date (baseline period) and in the 6 months following the index date (follow-up period). Achievement of glycated hemoglobin goals were established as <7%. RESULTS: We screened 2870 Mexican patients; 288 (10.03% received SGLT2 inhibitors). Mean age for both groups of patients was 57.68 ± 11.06 years. The dapagliflozin control rate was 19.56% and the canagliflozin control rate 18.96%. Monotherapy with SGLT2 inhibitors was used in 21 patients (6.25%). Overall HbA1c goals were met in 56 patients (19.44%) with similar results with dapagliflozin or canagliflozin. The combination of SGLT2 inhibitors and sulfonylureas had the highest control rate (30.30%) compared to other regimens. Monotherapy was present in 6.25%. Insulin requirement was associated with poor control (2.8% vs. 18.05%, P < 0.05, 95% CI [0.07, 0.84]). Combination therapy with DPP4 inhibitors was associated with better control (P < 0.05, 95% CI, [1.10, 3.92]). CONCLUSION: No difference between the drugs was observed. Real-world effectiveness data of SGLT2 inhibitors show that the percentage of patients reaching metabolic goals is low. SLGT2 inhibitors were used more frequently as combined therapy.
format Online
Article
Text
id pubmed-5493113
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54931132017-07-05 SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study Tamez-Perez, Héctor Eloy Delgadillo-Esteban, Enrique Soni-Duque, David Hernández-Coria, Mayra Ivonne Tamez-Peña, Alejandra Lorena J Diabetes Metab Disord Research Article BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. METHODS: A retrospective, observational study. Inclusion criteria for patients were a previous diagnosis of type 2 diabetes mellitus, age > 18 years, patients receiving either dapagliflozin 10 mg and/or canagliflozin 300 mg. We excluded pregnant patients, patients with type 1 diabetes mellitus and acute metabolic complications of diabetes. Patients included in the analysis were enrolled in a health plan at least 6 months prior to the index date (baseline period) and in the 6 months following the index date (follow-up period). Achievement of glycated hemoglobin goals were established as <7%. RESULTS: We screened 2870 Mexican patients; 288 (10.03% received SGLT2 inhibitors). Mean age for both groups of patients was 57.68 ± 11.06 years. The dapagliflozin control rate was 19.56% and the canagliflozin control rate 18.96%. Monotherapy with SGLT2 inhibitors was used in 21 patients (6.25%). Overall HbA1c goals were met in 56 patients (19.44%) with similar results with dapagliflozin or canagliflozin. The combination of SGLT2 inhibitors and sulfonylureas had the highest control rate (30.30%) compared to other regimens. Monotherapy was present in 6.25%. Insulin requirement was associated with poor control (2.8% vs. 18.05%, P < 0.05, 95% CI [0.07, 0.84]). Combination therapy with DPP4 inhibitors was associated with better control (P < 0.05, 95% CI, [1.10, 3.92]). CONCLUSION: No difference between the drugs was observed. Real-world effectiveness data of SGLT2 inhibitors show that the percentage of patients reaching metabolic goals is low. SLGT2 inhibitors were used more frequently as combined therapy. BioMed Central 2017-06-30 /pmc/articles/PMC5493113/ /pubmed/28680862 http://dx.doi.org/10.1186/s40200-017-0308-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tamez-Perez, Héctor Eloy
Delgadillo-Esteban, Enrique
Soni-Duque, David
Hernández-Coria, Mayra Ivonne
Tamez-Peña, Alejandra Lorena
SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
title SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
title_full SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
title_fullStr SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
title_full_unstemmed SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
title_short SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
title_sort sglt2 inhibitors as add on therapy in type 2 diabetes: a real world study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493113/
https://www.ncbi.nlm.nih.gov/pubmed/28680862
http://dx.doi.org/10.1186/s40200-017-0308-4
work_keys_str_mv AT tamezperezhectoreloy sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy
AT delgadilloestebanenrique sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy
AT soniduquedavid sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy
AT hernandezcoriamayraivonne sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy
AT tamezpenaalejandralorena sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy